Sign In
Buy TXMD
$1.97
-0.0700 (-3.43%)
At Close: Jun 03, 2026
TherapeuticsMD Announces First Quarter 2026 Financial Results
04:05pm, Tuesday, 12'th May 2026
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial res
TherapeuticsMD Announces Full Year 2025 Financial Results
04:05pm, Monday, 30'th Mar 2026
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial res
TherapeuticsMD Announces Third Quarter 2025 Financial Results
04:05pm, Wednesday, 12'th Nov 2025
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial res
Reviewing Journey Medical (NASDAQ:DERM) and TherapeuticsMD (NASDAQ:TXMD)
01:41am, Friday, 24'th Oct 2025
Journey Medical (NASDAQ: DERM - Get Free Report) and TherapeuticsMD (NASDAQ: TXMD - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two
TherapeuticsMD Announces Second Quarter 2025 Financial Results
04:05pm, Tuesday, 12'th Aug 2025
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial res
TherapeuticsMD Announces First Quarter 2025 Financial Results
04:05pm, Tuesday, 13'th May 2025
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial res
TherapeuticsMD Announces Full Year 2024 Financial Results
04:05pm, Thursday, 27'th Mar 2025
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial res
TherapeuticsMD And 2 Other Stocks Under $2 Executives Are Buying
07:36am, Monday, 26'th Aug 2024
The Dow Jones index closed higher by more than 450 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects.
TherapeuticsMD Announces First Quarter 2024 Financial Results
04:05pm, Friday, 10'th May 2024
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial res
TherapeuticsMD Announces Full Year 2023 Financial Results
04:00pm, Friday, 29'th Mar 2024
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial res
TherapeuticsMD Announces Third Quarter 2023 Financial Results
04:05pm, Tuesday, 14'th Nov 2023
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial res
TherapeuticsMD Announces Second Quarter 2023 Financial Results
06:50am, Monday, 14'th Aug 2023
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial res
TherapeuticsMD Announces First Quarter 2023 Financial Results
04:05pm, Monday, 15'th May 2023
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial res
All You Need to Know About TherapeuticsMD (TXMD) Rating Upgrade to Buy
01:42pm, Friday, 14'th Apr 2023
TherapeuticsMD (TXMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition
04:01pm, Friday, 07'th Apr 2023
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial res
